I very much believe that if we protect IP and at the same time ensure that we have proper pricing in this country and ensure good access to innovative medicines, we can in fact be an effective interlocutor, if I could say so, on the 10-year plan. I believe that access to innovative medicine saves lives and helps reduce hospitalization.
This other issue that has been brought to the table, which upsets some of the members, is an issue that has been debated in the industry committee. Unfortunately, the generics are misinterpreting the facts: it is not based on a Supreme Court decision. It does not extend patents; it does not increase prices. In fact, I would challenge the generics by saying it is their pricing regime that is thwarting innovation in this country.